What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Zabotti et al. IL23i guselkumab. Machine learning identified clusters of MDA response @RheumNow #EULAR2022 OP0259 https://t.co/67tfuADxLs https://t.co/33Y5m37K3y
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 POS0278:
Proof of concept US study:
💎CPP crystals do NOT generate posterior shadowing
💎MSU and hydroxyapatite did have shadowing, proportional to concentration of crystals
@Rheumnow @MymaAlbaydaMD @USSONAR_Rh
David Liew drdavidliew
3 years 6 months ago
There's nothing like a good physical examination
Temporal artery exam & ultrasound vs temporal artery biopsy
n=97 consecutive ?GCA pts from Carlo Salvarini's group
Very decent PPV
Those TA exam findings can be hard to find, but they're gold dust.
POS0820 #EULAR2022 @RheumNow https://t.co/X9TzIqQBaB
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 POS0213
Beware of paradoxical low lipids in RA!
⭐️ETN+MTX vs MTX T2T:
Early ETN: increased in HLD, lesser LDL, differs from MTX. Correlates with clinical disease activity
@RheumNow https://t.co/c6GXadVwYN
Dr. Rachel Tate uptoTate
3 years 6 months ago
SpA pregnancies in #EULAR2022 POS1051 found that 40% of pts flared, particularly during their 2nd trimester in those with axial involvement OR post-partum. Seven flares led to TNFi initiation in 2nd or 3rd trimesters and were without correlation in post-partum flares. @RheumNow https://t.co/0ZWjYMwmzn
Richard Conway RichardPAConway
3 years 6 months ago
Dr Patel @NaomiRheumMD et al. Avacopan in AAV at different thresholds toxicity. Minimum clinically important difference for GTI is 10 points. Avacopan assoc lower glucocorticoid toxicity irrespective of threshold used. @RheumNow #EULAR2022 POS0833 https://t.co/8iIIAsMOlI
Richard Conway RichardPAConway
3 years 6 months ago
Brevet et al. SAPHO syndrome. Divided into bone group and joint/mixed group. Better response to bisphosphonate in bone group 60% vs 6%. Better response to DMARD in joint/mixed group 94% vs 40% @RheumNow #EULAR2022 POS1333 https://t.co/FfYBIEGGgJ
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 POS0207
Fatigue in early RA:
⭐️Does not show direct effect between inflammation on fatigue
⭐️Suggests broader indirect effect of psychosocial aspects of wellbeing (pain, mental health, sleep, disease perception) plays larger role
@Rheumnow https://t.co/zTxk7kZRIX
Richard Conway RichardPAConway
3 years 6 months ago
Szekanecz et al. ORAL Surveillance. Geographic differences in MACE largely driven by history CVD and high baseline risk in North America and ROW. @RheumNow #EULAR2022 POS0110 https://t.co/cR6a7N2KP5
Richard Conway RichardPAConway
3 years 6 months ago
Unizony et al. GCA outcome on/after tocilizumab. 36.5% relapse after stopping tocilizumab. Generally stopped due to remission, 10% stopped due to adverse event @RheumNow #EULAR2022 POS0267 https://t.co/jlZDTinfCK
Dr. Antoni Chan synovialjoints
3 years 6 months ago
The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
David Liew drdavidliew
3 years 6 months ago
For psoriasis +MSK pain, should we be chasing synovitis/enthesitis on ultrasound?
PsO pts with MSK pain n=79
USS inflamm in 47%
Site-spec correlate only OR 3.1
Even if we act on USS:
PsA Rx is systemic, so overall impression is good enough anyway?
POS0131 #EULAR2022 @RheumNow https://t.co/O3P7J2Rskw
Robert B Chao, MD doctorRBC
3 years 6 months ago
Are wearable devices useful in assessing physical activity in rheumatic diseases?
Meta-analysis showed pts with rheumatic diseases reached recommended threshold for moderate to vigorous physical activity but not daily steps.
@RheumNow #EULAR2022 POST#POS0163
Poster Hall